{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:33:21Z","timestamp":1792798401118,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sailing Fund of Fujian Medical University","award":["2021QH2041"],"award-info":[{"award-number":["2021QH2041"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81400160"],"award-info":[{"award-number":["No. 81400160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2022J02036"],"award-info":[{"award-number":["2022J02036"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2023Y9021"],"award-info":[{"award-number":["2023Y9021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although bortezomib (BTZ) is the cornerstone of anti-multiple myeloma (MM) therapy, the inevitable primary and secondary drug resistance still seriously affects the prognosis of patients. New treatment strategies are in need. Sodium-calcium exchanger 1 (NCX1) is a calcium-permeable ion transporter on the membrane, and our previous studies showed that low NCX1 confers inferior viability in MM cells and suppressed osteoclast differentiation. However, the effect of NCX1 on BTZ sensitivity of MM and its possible mechanism remain unclear. In this study, we investigated the effect of NCX1 on BTZ sensitivity in MM, focusing on cellular processes of autophagy and cell viability. Our results provide evidence that NCX1 expression correlates with MM disease progression and low NCX1 expression increases BTZ sensitivity. NCX1\/Ca\n                    <jats:sup>2+<\/jats:sup>\n                    triggered autophagic flux through non-canonical NF\u03baB pathway in MM cells, leading to attenuated the sensitivity of BTZ. Knockdown or inhibition of NCX1 could potentiate the anti-MM activity of BTZ in vitro and vivo, and inhibition of autophagy sensitized NCX1-overexpressing MM cells to BTZ. In general, this work implicates NCX1 as a potential therapeutic target in MM with BTZ resistance and provides novel mechanistic insights into its vital role in combating BTZ resistance.\n                  <\/jats:p>","DOI":"10.1186\/s12964-024-01628-4","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T12:01:58Z","timestamp":1714996918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["NCX1\/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NF\u03baB signaling pathway"],"prefix":"10.1186","volume":"22","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"crossref","unstructured":"Murdaca G, Allegra A, Paladin F, Calapai F, Musolino C, Gangemi S. Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma. Int J Mol Sci. 2021;22(16):9039.","DOI":"10.3390\/ijms22169039"},{"issue":"5","key":"1628_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"4","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396\u2013406.","journal-title":"Haematologica"},{"issue":"39","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"25384","DOI":"10.18632\/oncotarget.25366","volume":"9","author":"BE Fitzwalter","year":"2018","unstructured":"Fitzwalter BE, Thorburn A. Autophagy inhibition improves anti-cancer drugs via FOXO3a activation. Oncotarget. 2018;9(39):25384\u20135.","journal-title":"Oncotarget"},{"key":"1628_CR5","doi-asserted-by":"crossref","unstructured":"Pang X, Zhang X, Jiang Y, Su Q, Li Q, Li Z. Autophagy: mechanisms and therapeutic potential of flavonoids in cancer. Biomolecules. 2021;11(2):135.","DOI":"10.3390\/biom11020135"},{"issue":"1","key":"1628_CR6","first-page":"84","volume":"5","author":"F Yao","year":"2012","unstructured":"Yao F, Wang G, Wei W, Tu Y, Tong H, Sun S. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Mol Med Rep. 2012;5(1):84\u20138.","journal-title":"Mol Med Rep"},{"issue":"6","key":"1628_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00280-013-2156-3","volume":"71","author":"AM Escalante","year":"2013","unstructured":"Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol. 2013;71(6):1567\u201376.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1002\/cncr.27586","volume":"118","author":"B Hui","year":"2012","unstructured":"Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, Yang H, Liu WR, Shi GM, Fan J. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer. 2012;118(22):5560\u201371.","journal-title":"Cancer"},{"issue":"8","key":"1628_CR9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10(8):1380\u201390.","journal-title":"Autophagy"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"352794","DOI":"10.1155\/2015\/352794","volume":"2015","author":"E Kania","year":"2015","unstructured":"Kania E, Paj\u0105k B, Orzechowski A. Calcium homeostasis and ER stress in control of autophagy in cancer cells. BioMed Res Int. 2015;2015:352794.","journal-title":"BioMed Res Int"},{"issue":"5","key":"1628_CR11","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1002\/jcp.27432","volume":"234","author":"B Cao","year":"2019","unstructured":"Cao B, Dai X, Wang W. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca(2+) -calcineurin-NFATc1 pathway. J Cell Physiol. 2019;234(5):6831\u201341.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1124\/jpet.110.172809","volume":"337","author":"N Yanamandra","year":"2011","unstructured":"Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther. 2011;337(3):636\u201343.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ijc.28149","volume":"133","author":"IS Song","year":"2013","unstructured":"Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS, Rhee BD, Han J. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer. 2013;133(6):1357\u201367.","journal-title":"Int J Cancer"},{"issue":"12","key":"1628_CR14","first-page":"4264","volume":"28","author":"NJ Gerkau","year":"2018","unstructured":"Gerkau NJ, Rakers C, Durry S, Petzold GC, Rose CR. Reverse NCX Attenuates Cellular Sodium Loading in Metabolically Compromised Cortex. Cerebral Cortex (New York, NY\u202f: 1991). 2018;28(12):4264\u201380.","journal-title":"Cerebral Cortex (New York, NY : 1991)"},{"issue":"39","key":"1628_CR15","doi-asserted-by":"publisher","first-page":"63816","DOI":"10.18632\/oncotarget.11695","volume":"7","author":"J Wen","year":"2016","unstructured":"Wen J, Pang Y, Zhou T, Qi X, Zhao M, Xuan B, Meng X, Guo Y, Liu Q, Liang H, et al. Essential role of Na+\/Ca2+ exchanger 1 in smoking-induced growth and migration of esophageal squamous cell carcinoma. Oncotarget. 2016;7(39):63816\u201328.","journal-title":"Oncotarget"},{"issue":"3","key":"1628_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/carcin\/bgw004","volume":"37","author":"J Xu","year":"2016","unstructured":"Xu J, Ji B, Wen G, Yang Y, Jin H, Liu X, Xie R, Song W, Song P, Dong H, et al. Na+\/H+ exchanger 1, Na+\/Ca2+ exchanger 1 and calmodulin complex regulates interleukin 6-mediated cellular behavior of human hepatocellular carcinoma. Carcinogenesis. 2016;37(3):290\u2013300.","journal-title":"Carcinogenesis"},{"issue":"27","key":"1628_CR17","doi-asserted-by":"publisher","first-page":"42059","DOI":"10.18632\/oncotarget.9806","volume":"7","author":"Z Long","year":"2016","unstructured":"Long Z, Chen B, Liu Q, Zhao J, Yang Z, Dong X, Xia L, Huang S, Hu X, Song B, et al. The reverse-mode NCX1 activity inhibitor KB-R7943 promotes prostate cancer cell death by activating the JNK pathway and blocking autophagic flux. Oncotarget. 2016;7(27):42059\u201370.","journal-title":"Oncotarget"},{"issue":"16","key":"1628_CR18","doi-asserted-by":"publisher","first-page":"12673","DOI":"10.3390\/ijms241612673","volume":"24","author":"F Brandalise","year":"2023","unstructured":"Brandalise F, Ramieri M, Pastorelli E, Priori EC, Ratto D, Venuti MT, Roda E, Talpo F, Rossi P. Role of Na+\/Ca2+ Exchanger (NCX) in Glioblastoma Cell Migration (In Vitro). Int J Mol Sci. 2023;24(16):12673.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"1628_CR19","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1111\/bph.14692","volume":"176","author":"HJ Hu","year":"2019","unstructured":"Hu HJ, Wang SS, Wang YX, Liu Y, Feng XM, Shen Y, Zhu L, Chen HZ, Song M. Blockade of the forward Na+ \/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+ -mediated cell death. Br J Pharmacol. 2019;176(15):2691\u2013707.","journal-title":"Br J Pharmacol"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"113695","DOI":"10.1016\/j.bcp.2019.113695","volume":"171","author":"B Chovancova","year":"2020","unstructured":"Chovancova B, Liskova V, Miklikova S, Hudecova S, Babula P, Penesova A, Sevcikova A, Durinikova E, Novakova M, Matuskova M, et al. Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment. Biochem Pharmacol. 2020;171:113695.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"1628_CR21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10238-022-00905-1","volume":"23","author":"T Li","year":"2023","unstructured":"Li T, Qiu D, Chen Q, Yang A, Chen J, Zeng Z. NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK\/c-Fos\/NFATc1 signaling pathway in multiple myeloma. Clin Exp Med. 2023;23(5):1581\u201396.","journal-title":"Clin Exp Med"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.","journal-title":"Nat Commun"},{"issue":"1","key":"1628_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-021-01380-0","volume":"20","author":"C Gu","year":"2021","unstructured":"Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, et al. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021;20(1):84.","journal-title":"Mol Cancer"},{"issue":"5","key":"1628_CR24","first-page":"469","volume":"61","author":"Z Cai","year":"2022","unstructured":"Cai Z, Chen WM. Interpretation of treatment of relapsed\/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Zhonghua Nei Ke Za Zhi. 2022;61(5):469\u201373.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"15","key":"1628_CR25","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1628_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13045-020-00993-0","volume":"13","author":"K Beider","year":"2020","unstructured":"Beider K, Rosenberg E, Dimenshtein-Voevoda V, Sirovsky Y, Vladimirsky J, Magen H, Ostrovsky O, Shimoni A, Bromberg Z, Weiss L, et al. Blocking of transient receptor potential vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. J Hematol Oncol. 2020;13(1):158.","journal-title":"J Hematol Oncol"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.leukres.2022.106967","volume":"123","author":"X Zang","year":"2022","unstructured":"Zang X, Wang J, Xia Y, Li J, Chen L, Gu Y, Shen X. LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma. Leukemia Res. 2022;123:106967.","journal-title":"Leukemia Res"},{"issue":"7","key":"1628_CR28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","volume":"11","author":"E Milan","year":"2015","unstructured":"28. Milan E, Perini T, Resnati M, Orfanelli U, Oliva L, Raimondi A, Cascio P, Bachi A, Marcatti M, Ciceri F, et al. A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy. 2015;11(7):1161\u201378.","journal-title":"Autophagy"},{"key":"1628_CR29","doi-asserted-by":"crossref","unstructured":"Rahman MA, Cho Y, Nam G, Rhim H: Antioxidant Compound, Oxyresveratrol, Inhibits APP Production through the AMPK\/ULK1\/mTOR-Mediated Autophagy Pathway in Mouse Cortical Astrocytes. Antioxidants (Basel, Switzerland). 2021;10(3):408.","DOI":"10.3390\/antiox10030408"},{"issue":"1","key":"1628_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3892\/ol.2016.4597","volume":"12","author":"A Yerlikaya","year":"2016","unstructured":"Yerlikaya A, Erdo\u011fan E, Okur E, Yerlikaya \u015e, Savran B. A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncol Lett. 2016;12(1):323\u201330.","journal-title":"Oncol Lett"},{"issue":"3","key":"1628_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3727\/096504017X15049221237147","volume":"26","author":"H Zhang","year":"2018","unstructured":"Zhang H, Pang Y, Ma C, Li J, Wang H, Shao Z. ClC5 decreases the sensitivity of multiple myeloma cells to bortezomib via promoting prosurvival autophagy. Oncol Res. 2018;26(3):421\u20139.","journal-title":"Oncol Res"},{"issue":"12","key":"1628_CR32","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.7150\/thno.15584","volume":"6","author":"M Roy","year":"2016","unstructured":"Roy M, Liang L, Xiao X, Peng Y, Luo Y, Zhou W, Zhang J, Qiu L, Zhang S, Liu F, et al. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma. Theranostics. 2016;6(12):2209\u201324.","journal-title":"Theranostics"},{"issue":"21","key":"1628_CR33","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-16-0595","volume":"76","author":"H Zhang","year":"2016","unstructured":"Zhang H, Chen Z, Miranda RN, Medeiros LJ, McCarty N. TG2 and NF-\u03baB signaling coordinates the survival of mantle cell lymphoma cells via il6-mediated autophagy. Cancer Res. 2016;76(21):6410\u201323.","journal-title":"Cancer Res"},{"issue":"2","key":"1628_CR34","doi-asserted-by":"publisher","first-page":"e32584","DOI":"10.1371\/journal.pone.0032584","volume":"7","author":"L Jia","year":"2012","unstructured":"Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-\u03baB activation by reducing I-\u03baB\u03b1 degradation in lymphoma cells. PloS One. 2012;7(2):e32584.","journal-title":"PloS One"},{"key":"1628_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updates. 2015;18:18\u201335.","journal-title":"Drug Resist Updates"},{"issue":"9","key":"1628_CR36","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jxb\/erab063","volume":"72","author":"ME P\u00e9rez-P\u00e9rez","year":"2021","unstructured":"P\u00e9rez-P\u00e9rez ME, Lemaire SD, Crespo JL. The ATG4 protease integrates redox and stress signals to regulate autophagy. J Exp Bot. 2021;72(9):3340\u201351.","journal-title":"J Exp Bot"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejps.2019.04.011","volume":"134","author":"NM Kocaturk","year":"2019","unstructured":"Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci. 2019;134:116\u201337.","journal-title":"Eur J Pharm Sci"},{"key":"1628_CR38","doi-asserted-by":"crossref","unstructured":"Di Lernia G, Leone P, Solimando AG, Buonavoglia A, Saltarella I, Ria R, Ditonno P, Silvestris N, Crudele L, Vacca A et al. Bortezomib treatment modulates autophagy in multiple myeloma. J Clin Med. 2020;9(2):552.","DOI":"10.3390\/jcm9020552"},{"issue":"3","key":"1628_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1158\/0008-5472.CAN-13-2966","volume":"74","author":"DA Gewirtz","year":"2014","unstructured":"39. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74(3):647\u201351.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1628_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10875-016-0254-9","volume":"36","author":"E Milan","year":"2016","unstructured":"Milan E, Fabbri M, Cenci S. Autophagy in plasma cell ontogeny and malignancy. J Clin Immunol. 2016;36(Suppl 1):18\u201324.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1628_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/1878-0261.12641","volume":"14","author":"J Xia","year":"2020","unstructured":"Xia J, He Y, Meng B, Chen S, Zhang J, Wu X, Zhu Y, Shen Y, Feng X, Guan Y, et al. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol. 2020;14(4):763\u201378.","journal-title":"Mol Oncol"},{"issue":"23","key":"1628_CR42","doi-asserted-by":"publisher","first-page":"12358","DOI":"10.18632\/oncotarget.2590","volume":"5","author":"S Jaganathan","year":"2014","unstructured":"Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. Oncotarget. 2014;5(23):12358\u201370.","journal-title":"Oncotarget"},{"issue":"35","key":"1628_CR43","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1038\/s41388-022-02412-9","volume":"41","author":"H Wan","year":"2022","unstructured":"Wan H, Gao N, Lu W, Lu C, Chen J, Wang Y, Dong H. NCX1 coupled with TRPC1 to promote gastric cancer via Ca(2+)\/AKT\/\u03b2-catenin pathway. Oncogene. 2022;41(35):4169\u201382.","journal-title":"Oncogene"},{"key":"1628_CR44","doi-asserted-by":"crossref","unstructured":"Liu Z, Cheng Q, Ma X, Song M. Suppressing effect of Na(+)\/Ca(2+) Exchanger (NCX) inhibitors on the growth of melanoma cells. Int J Mol Sci. 2022;23(2):901.","DOI":"10.3390\/ijms23020901"},{"issue":"3","key":"1628_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3748\/wjg.v25.i3.287","volume":"25","author":"QS Liao","year":"2019","unstructured":"Liao QS, Du Q, Lou J, Xu JY, Xie R. Roles of Na(+)\/Ca(2+) exchanger 1 in digestive system physiology and pathophysiology. World J Gastroenterol. 2019;25(3):287\u201399.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1628_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3892\/ijmm.2020.4831","volume":"47","author":"J Wang","year":"2021","unstructured":"Wang J, Chen J, Qiu D, Zeng Z. Regulatory role of DEPTOR-mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma. Int J Mol Med. 2021;47(2):643\u201358.","journal-title":"Int J Mol Med"},{"key":"1628_CR47","doi-asserted-by":"publisher","first-page":"585286","DOI":"10.3389\/fphar.2021.585286","volume":"12","author":"H Dai","year":"2021","unstructured":"Dai H, Ma B, Dai X, Pang J, Wang J, Zhao Y, Wang M, Zhang H, Gao H, Qian S, Tian F, Sun X. Shengma Biejia decoction Inhibits cell growth in multiple myeloma by inducing autophagy-mediated apoptosis through the ERK\/mTOR pathway. Front Pharmacol. 2021;12:585286.","journal-title":"Front Pharmacol"},{"key":"1628_CR48","doi-asserted-by":"publisher","first-page":"6096391","DOI":"10.1155\/2020\/6096391","volume":"2020","author":"X Wu","year":"2020","unstructured":"Wu X, Liu Y, Zhang E, Chen J, Huang X, Yan H, Cao W, Qu J, Gu H, Xu R, He J, Cai Z. Dihydroartemisinin modulates apoptosis and autophagy in multiple myeloma through the P38\/MAPK and Wnt\/\u03b2-catenin signaling pathways. Oxid Med Cell Longev. 2020;2020:6096391.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"1628_CR49","first-page":"162","volume":"2","author":"R Feinman","year":"2004","unstructured":"Feinman R, Siegel DS, Berenson J. Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol. 2004;2(3):162\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1628_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.canlet.2021.08.009","volume":"520","author":"H Yi","year":"2021","unstructured":"Yi H, Liang L, Wang H, Luo S, Hu L, Wang Y, Shen X, Xiao L, Zhang Y, Peng H, et al. Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Lett. 2021;520:307\u201320.","journal-title":"Cancer Lett"},{"issue":"5","key":"1628_CR51","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060\u20136.","journal-title":"Blood"},{"issue":"5","key":"1628_CR52","doi-asserted-by":"publisher","first-page":"e0127334","DOI":"10.1371\/journal.pone.0127334","volume":"10","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Zhang K, Li G, Zhang X, Shi D. Expression of GITR enhances multiple myeloma cell sensitivity to bortezomib. PloS one. 2015;10(5):e0127334.","journal-title":"PloS one"},{"key":"1628_CR53","doi-asserted-by":"crossref","unstructured":"Lim SK, Peng CC, Low S, Vijay V, Budiman A, Phang BH, Lim JQ, Jeyasekharan AD, Lim ST, Ong CK et al: Sustained activation of non-canonical NF-\u03baB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia. 2022;23(2):901.","DOI":"10.1038\/s41375-022-01769-w"},{"issue":"4","key":"1628_CR54","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1002\/cti2.1386","volume":"11","author":"N Li","year":"2022","unstructured":"Li N, Zheng X, Chen M, Huang L, Chen L, Huo R, Li X, Huang Y, Sun M, Mai S, et al. Deficient DNASE1L3 facilitates neutrophil extracellular traps-induced invasion via cyclic GMP-AMP synthase and the non-canonical NF-\u03baB pathway in diabetic hepatocellular carcinoma. Clin Transl Immunol. 2022;11(4):e1386.","journal-title":"Clin Transl Immunol"},{"key":"1628_CR55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ceca.2018.07.003","volume":"74","author":"CT Berry","year":"2018","unstructured":"Berry CT, May MJ, Freedman BD. STIM- and Orai-mediated calcium entry controls NF-\u03baB activity and function in lymphocytes. Cell Calcium. 2018;74:131\u201343.","journal-title":"Cell Calcium"},{"issue":"1","key":"1628_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15210","volume":"182","author":"CT Wallington-Beddoe","year":"2018","unstructured":"56. Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, Pitson SM. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol. 2018;182(1):11\u201328.","journal-title":"Br J Haematol"},{"key":"1628_CR57","doi-asserted-by":"crossref","unstructured":"Chhabra S: Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals (Basel, Switzerland). 2017;10(2):40.","DOI":"10.3390\/ph10020040"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-01628-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T13:03:35Z","timestamp":1715000615000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-01628-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3776793\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. Informed consent was obtained according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}